Axsome Therapeutics, Inc.
https://axsome.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Axsome Therapeutics, Inc.
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
Axsome Succeeds In Narcolepsy Phase III, But Is That Enough?
Analysts say reboxetine looks approvable for cataplexy related to narcolepsy, but debate how broadly the drug may be adopted in a generic-laden therapeutic space.
Otsuka Counts The Cost Of Alzheimer’s Agitation Fail
The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice